IL134193A0 - O-substituted hydroxycumaranone derivatives as antitumor and antimetastatic agents - Google Patents
O-substituted hydroxycumaranone derivatives as antitumor and antimetastatic agentsInfo
- Publication number
- IL134193A0 IL134193A0 IL13419398A IL13419398A IL134193A0 IL 134193 A0 IL134193 A0 IL 134193A0 IL 13419398 A IL13419398 A IL 13419398A IL 13419398 A IL13419398 A IL 13419398A IL 134193 A0 IL134193 A0 IL 134193A0
- Authority
- IL
- Israel
- Prior art keywords
- hydroxycumaranone
- antitumor
- derivatives
- substituted
- antimetastatic agents
- Prior art date
Links
- VQTUMNNCKYTZSR-UHFFFAOYSA-N 3-hydroxy-3h-1-benzofuran-2-one Chemical class C1=CC=C2C(O)C(=O)OC2=C1 VQTUMNNCKYTZSR-UHFFFAOYSA-N 0.000 title 1
- 230000000259 anti-tumor effect Effects 0.000 title 1
- 239000002257 antimetastatic agent Substances 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/83—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97113190 | 1997-07-31 | ||
| EP98106946 | 1998-04-16 | ||
| PCT/EP1998/004619 WO1999006387A2 (en) | 1997-07-31 | 1998-07-23 | O-substituted hydroxycumaranone derivatives as antitumor and antimetastatic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL134193A0 true IL134193A0 (en) | 2001-04-30 |
Family
ID=26145681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL13419398A IL134193A0 (en) | 1997-07-31 | 1998-07-23 | O-substituted hydroxycumaranone derivatives as antitumor and antimetastatic agents |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US6200989B1 (es) |
| EP (1) | EP1012147B1 (es) |
| JP (1) | JP3241711B2 (es) |
| KR (1) | KR100343067B1 (es) |
| AR (1) | AR013374A1 (es) |
| AT (1) | ATE308535T1 (es) |
| AU (1) | AU745839B2 (es) |
| BR (1) | BR9811589A (es) |
| CA (1) | CA2296476A1 (es) |
| DE (1) | DE69832184D1 (es) |
| HR (1) | HRP20000031A2 (es) |
| HU (1) | HUP0004221A2 (es) |
| ID (1) | ID24525A (es) |
| IL (1) | IL134193A0 (es) |
| MA (1) | MA26528A1 (es) |
| NO (1) | NO20000366D0 (es) |
| PE (1) | PE106099A1 (es) |
| PL (1) | PL338614A1 (es) |
| TR (1) | TR200000272T2 (es) |
| UY (1) | UY25114A1 (es) |
| WO (1) | WO1999006387A2 (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU736869B2 (en) * | 1999-01-30 | 2001-08-02 | Roche Diagnostics Gmbh | O-substituted hydroxycoumaranone derivatives as antitumor and antimetastatic agents |
| WO2003046207A2 (en) * | 2001-11-27 | 2003-06-05 | Fred Hutchinson Cancer Research Center | Methods for inhibiting deacetylase activity |
| AU2002358158A1 (en) * | 2001-12-19 | 2003-06-30 | D. Collen Research Foundation | Use of urokinase receptor antagonists to modulate ischemiareperfusion injury |
| WO2004076444A2 (en) * | 2003-02-25 | 2004-09-10 | F. Hoffmann-La Roche Ag | Novel hydroxycoumaranone derivatives as antitumor and antimetastatic |
| ES2535436T3 (es) * | 2006-10-27 | 2015-05-11 | The University Of Tokyo | Compuesto amídico o sal del mismo, e inhibidor de la formación de biopelícula, eliminador de biopelícula, y bactericida, utilizando cada uno el compuesto amídico o la sal del mismo |
| US8258307B2 (en) | 2006-11-07 | 2012-09-04 | University Of Tokyo | Amide compound or salt thereof, and biofilm inhibitor, biofilm remover and disinfectant containing the same |
| GB2460915B (en) | 2008-06-16 | 2011-05-25 | Biovascular Inc | Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor |
| PT109740B (pt) * | 2016-11-14 | 2020-07-30 | Hovione Farmaciencia Sa | Processo para a preparação de brometo de umeclidínio |
| ES2919779T3 (es) | 2017-06-20 | 2022-07-28 | Imbria Pharmaceuticals Inc | Derivado de 1-[(2,3,4-trimetoxifenil)metil]-piperazina, composiciones del mismo y métodos para aumentar la eficiencia del metabolismo cardíaco |
| CA3073656C (en) | 2017-09-22 | 2024-03-05 | Jubilant Epipad LLC | Heterocyclic compounds as pad inhibitors |
| CN111225915B (zh) | 2017-10-18 | 2023-03-07 | 朱比兰特埃皮帕德有限公司 | 作为pad抑制剂的咪唑并吡啶化合物 |
| EP3707135A1 (en) | 2017-11-06 | 2020-09-16 | Jubilant Prodel LLC | Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation |
| BR112020010322A2 (pt) | 2017-11-24 | 2020-11-17 | Jubilant Episcribe Llc | composto da fórmula i; composto da fórmula ia; composto da fórmula ib; processo de preparação de compostos da fórmula i; composição farmacêutica; método para o tratamento e/ou prevenção de várias doenças; uso dos compostos; método para o tratamento de câncer; e método para o tratamento e/ou prevenção de uma afecção mediada por prmt5 ou um distúrbio proliferativo ou câncer |
| MX2020006115A (es) | 2017-12-13 | 2020-11-09 | Praxis Biotech LLC | Inhibidores de la vía de respuesta al estrés integrada. |
| SG11202008950PA (en) | 2018-03-13 | 2020-10-29 | Jubilant Prodel LLC | Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation |
| KR20210021519A (ko) * | 2018-06-05 | 2021-02-26 | 프락시스 바이오테크 엘엘씨 | 통합 스트레스 반응 경로의 저해제 |
| US11318133B2 (en) | 2019-06-12 | 2022-05-03 | Praxis Biotech LLC | Modulators of integrated stress response pathway |
| US11530184B2 (en) | 2020-06-30 | 2022-12-20 | Imbria Pharmaceuticals, Inc. | Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
| US11780811B2 (en) | 2020-06-30 | 2023-10-10 | Imbria Pharmaceuticals, Inc. | Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
| US11883396B2 (en) | 2021-05-03 | 2024-01-30 | Imbria Pharmaceuticals, Inc. | Methods of treating kidney conditions using modified forms of trimetazidine |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2901336A1 (de) | 1979-01-15 | 1980-07-24 | Boehringer Mannheim Gmbh | Neue arylether, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel |
| DE3209271A1 (de) * | 1982-03-13 | 1983-09-15 | Boehringer Mannheim Gmbh, 6800 Mannheim | Bicyclische phenolether, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel |
| DE3587711T2 (de) * | 1984-08-13 | 1994-04-28 | Biotech Australia Pty Ltd | Minaktivin. |
| US5747458A (en) * | 1995-06-07 | 1998-05-05 | Chiron Corporation | Urokinase receptor ligands |
-
1998
- 1998-07-23 JP JP2000505146A patent/JP3241711B2/ja not_active Expired - Fee Related
- 1998-07-23 EP EP98943771A patent/EP1012147B1/en not_active Expired - Lifetime
- 1998-07-23 DE DE69832184T patent/DE69832184D1/de not_active Expired - Lifetime
- 1998-07-23 AT AT98943771T patent/ATE308535T1/de not_active IP Right Cessation
- 1998-07-23 BR BR9811589-8A patent/BR9811589A/pt not_active Application Discontinuation
- 1998-07-23 IL IL13419398A patent/IL134193A0/xx unknown
- 1998-07-23 PL PL98338614A patent/PL338614A1/xx not_active Application Discontinuation
- 1998-07-23 TR TR2000/00272T patent/TR200000272T2/xx unknown
- 1998-07-23 HU HU0004221A patent/HUP0004221A2/hu unknown
- 1998-07-23 KR KR1020007000941A patent/KR100343067B1/ko not_active IP Right Cessation
- 1998-07-23 WO PCT/EP1998/004619 patent/WO1999006387A2/en not_active Application Discontinuation
- 1998-07-23 ID IDW20000173A patent/ID24525A/id unknown
- 1998-07-23 CA CA002296476A patent/CA2296476A1/en not_active Abandoned
- 1998-07-23 AU AU91559/98A patent/AU745839B2/en not_active Ceased
- 1998-07-29 AR ARP980103732A patent/AR013374A1/es unknown
- 1998-07-29 UY UY25114A patent/UY25114A1/es not_active Application Discontinuation
- 1998-07-30 PE PE1998000679A patent/PE106099A1/es not_active Application Discontinuation
- 1998-07-31 MA MA25200A patent/MA26528A1/fr unknown
-
1999
- 1999-09-22 US US09/401,403 patent/US6200989B1/en not_active Expired - Fee Related
-
2000
- 2000-01-20 HR HR20000031A patent/HRP20000031A2/hr not_active Application Discontinuation
- 2000-01-25 NO NO20000366A patent/NO20000366D0/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PL338614A1 (en) | 2000-11-06 |
| AU745839B2 (en) | 2002-04-11 |
| NO20000366L (no) | 2000-01-25 |
| MA26528A1 (fr) | 2004-12-20 |
| AU9155998A (en) | 1999-02-22 |
| ATE308535T1 (de) | 2005-11-15 |
| KR100343067B1 (ko) | 2002-07-03 |
| AR013374A1 (es) | 2000-12-27 |
| CA2296476A1 (en) | 1999-02-11 |
| JP2001512113A (ja) | 2001-08-21 |
| US6200989B1 (en) | 2001-03-13 |
| KR20010022362A (ko) | 2001-03-15 |
| NO20000366D0 (no) | 2000-01-25 |
| PE106099A1 (es) | 1999-11-11 |
| UY25114A1 (es) | 2001-01-31 |
| HUP0004221A2 (hu) | 2001-04-28 |
| HRP20000031A2 (en) | 2000-10-31 |
| BR9811589A (pt) | 2000-09-19 |
| DE69832184D1 (de) | 2005-12-08 |
| ID24525A (id) | 2000-07-20 |
| EP1012147A2 (en) | 2000-06-28 |
| TR200000272T2 (tr) | 2000-09-21 |
| WO1999006387A3 (en) | 1999-04-22 |
| WO1999006387A2 (en) | 1999-02-11 |
| JP3241711B2 (ja) | 2001-12-25 |
| EP1012147B1 (en) | 2005-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EG24081A (en) | 4-Substituted-9-deoxo-9a-aza-9a-homerythromycin derivatives | |
| AP9801389A0 (en) | Thienopyrimidine and thienoopyridine derivatives useful as anticancer agents | |
| HUP0003642A3 (en) | N-alkanoylphenylalanine derivatives | |
| GB9702194D0 (en) | Sulphonide derivatives | |
| ZA987602B (en) | N-alkanoylphenylalanine derivatives | |
| AP9700954A0 (en) | 6-ohenylpyridyl-2-amine derivatives | |
| AP9701156A0 (en) | 6-phenylpyridyl-2-amine derivatives | |
| IL134193A0 (en) | O-substituted hydroxycumaranone derivatives as antitumor and antimetastatic agents | |
| HUP9801168A3 (en) | Triazinylaminostilbene derivatives | |
| HUP9902993A3 (en) | Alkylaminobenzothiazole and -benzoxazole derivatives | |
| HUP9701835A3 (en) | Vinyl-pirrolidinone-cephalosporin derivatives | |
| IL132982A0 (en) | Cis-disubstituted aminocycloalkyl-pyrrolidine derivatives | |
| IL125149A0 (en) | Pyrazol-4-yl-hetaroyl derivatives | |
| GB9715821D0 (en) | Amidino-camptothecin derivatives | |
| GB2321457B (en) | 5-Aroylnaphthalene derivatives | |
| HU9701479D0 (en) | N-benzylazolium derivatives | |
| GB9604996D0 (en) | Benzodiazonine derivatives | |
| HUP0001792A3 (en) | Dibenzo-oxazepine and-dioxepine derivatives and their use as anti-tumor agents | |
| GB9725541D0 (en) | Amino-benzothiazole derivatives | |
| ZA98611B (en) | Imino-aza-anthracyclinone derivatives | |
| GB9600063D0 (en) | Guaridine derivatives | |
| GB9603226D0 (en) | Heterocyclyl-ergoline derivatives | |
| ZA983116B (en) | Arylsecocholadiene derivatives | |
| EP0998924A4 (en) | ANTINEOPLASTIC AGENTS | |
| ZA986683B (en) | O-substituted hydroxycumaranone derivatives as antitumor and antimetastatic agents |